Exploratory biomarker testing: to qualify or validate the assay?

Summary

In this column for Bioanalysis Zone, BioAgilytix’s Global Chief Scientific Officer, Dr. Afshin Safavi, discusses how applying the concepts of ‘fit-for-purpose’ (FFP) and ‘context of use’ (COU) can help in constructing biomarker assays that adequately meet investigation goals.

Click for full article

Featured Expert

Dr. Jennifer Zemo, Director

Sam Witherspoon, Scientist III

Dr. Frank Wischnewski, Associate Director

Dave Williams, Director, Bioanalytical Operations

Bindu Upadhyay, Manager II and Bioanalytical Project Manager

Dr. Florian Unger, Principal Investigator

Dr. Hui-I Tom, Director

Dr. Florian Sieglitz, Principal Investigator

Dr. Janett Schwarz, Principal Investigator

David Rusnak, Director, Bioanalytical Operations

Dr. Imke Müller, Director, Principal Investigator

Dr. Michelle Miller, Manager II

Yang Liu, Associate Director

Kathryn Lindley, Vice President, Operations

Todd Lester, Associate Director

Peter Leitner, Automation Lead

Laura Lassen, Director

Timothy Lansing, Manager II

Matthew Langevin, Director, Bioanalytical Operations

Jennifer Johnson, Manager I

Dr. Janina Hajek, Principal Investigator

Carla Gibbons, QA Director

Dr. Christine DiMeglio, Manager II

John Daw, Manager I

Dr. Kathy Bortoff, Scientist III

Luke Armstrong, Manager II

Krystal Alligood, Associate Director

Dr. Lydia Michaut, Scientific Officer

Anita Simkins, Vice President, Global Quality Assurance

Dr. Steven Michael, Senior Vice President and Chief Operating Officer

Dr. Afshin Safavi, Founder & Board Member

Dr. Dominique Gouty, USA Chief Scientific Officer

PD Dr. Arno Kromminga, Senior Vice President and Global Chief Scientific Officer